Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. - Wikidata - awgldk - TriplyDB

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

http://www.wikidata.org/entity/Q36807446

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials Disease severity is associated with the use of complementary medicine to treat or manage type-2 diabetes: data from the 2002 and 2007 National Health Interview Survey.Management of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: an observational study.Cost-effectiveness of Adolescent Bariatric Surgery Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial.Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms.Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE The burden of diabetes in Argentina.Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes.Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes.A multicentre demonstration project to evaluate the effectiveness and acceptability of the web-based Joint Asia Diabetes Evaluation (JADE) programme with or without nurse support in Chinese patients with Type 2 diabetes Intensified multifactorial treatment of patients with Type 2 diabetes: what can be achieved and does it pay off?Screening for type 2 diabetes and dysglycemia.Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.Glucose perturbations and cardiovascular risk: challenges and opportunities.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Quality improvement in diabetes--successful in achieving better care with hopes for prevention.Glucose targets for preventing diabetic kidney disease and its progression.Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.Intensive multifactorial treatment modifies the effect of family history of diabetes on glycaemic control in people with Type 2 diabetes: a post hoc analysis of the ADDITION-Denmark randomized controlled trial.Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study.Early identification of type 2 diabetes: policy should be aligned with health systems strengthening.Diabetes guidelines may delay timely adjustments during treatment and might contribute to clinical inertia.Intensive diabetes management for high-risk patients: how best to deliver?Clinical, metabolic and psychological outcomes and treatment costs of a prospective randomized trial based on different educational strategies to improve diabetes care (PRODIACOR).Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.Cost-effectiveness of diabetes self-management programs in community primary care settings.The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial.Determining optimal policy for emergency department using Markov decision process The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial (Preprint)

P2860

Q22241786-B36B7225-A6B1-4E4A-845C-3B34AB8DFA57 Q24186667-CD5D6A80-6B5A-4BF0-A9D7-DC8AB70CB9FE Q24194514-82571A98-1EA1-4BE8-82F4-57B6B78CB7BE Q24202505-1AE890F9-DB7C-4DB5-A901-BA5853FE7296 Q24236456-597188AD-23BC-4603-A783-E37E2F52C2AF Q33444254-F22412E4-B434-4EFF-A391-EAE66147FA4A Q33602120-4AB5B272-F265-41C3-A5B4-CDFE51FBCFFC Q34083400-54704FE7-E3C8-4F3C-954C-855BCEBD2350 Q34454292-7AB982A5-7592-4EC3-B795-88DE1F8D00E0 Q35110368-42CB8B79-5571-4FAE-80F5-A77871B7D651 Q35827536-89B9EF30-6C18-4C4D-A762-36FC8601C493 Q35877943-CF140E4B-F1F9-4274-929D-FE5EA08C8BF9 Q36112385-FAD0663A-6112-4B86-9D3F-634F5290E35D Q36205231-93451CDB-309E-47F0-B3B3-4DA3981B0068 Q36510353-05A953F5-53A5-42FB-B40F-9304F6433222 Q36713102-CB03DDC5-13C7-4721-BE31-8CF4DBD3E009 Q37193496-6DB0ED32-3AC2-4EDC-B174-8BA511A68E6A Q37404411-7AC866EA-23BE-4FFB-986E-37FE4E1F5802 Q37624295-CE57EF3E-7A49-46BF-9155-38BC209FD3A5 Q37663930-20368C11-9743-44C7-9D3B-7349799F9239 Q37798572-995868DC-FFA0-4700-9AA6-2C23E266D7BB Q37882225-E67F4BC7-25EE-4E38-8FA9-399CF36B9238 Q37973129-0839BBD6-1A61-4CA4-892C-B3D9AA225C29 Q38023286-B9C65B24-8857-4CB3-AE39-4B5F930F0EAD Q38039980-2A9BC0D0-394C-4451-92AB-3523A9F4C220 Q38614811-D6FA13CD-A5B4-4951-B5E6-FF4E5C9F271E Q38736800-FA6D85BC-0394-4E99-AF66-635ED54B8667 Q39331320-133095ED-74C8-4E0E-BADA-F747908AAE84 Q41145702-57D1FA65-C4DF-43E1-A01F-D88C7EEA2AE7 Q41776334-E2B8C22E-2CD6-44B4-B27A-79E1957BA394 Q42547700-E8002626-9A77-4352-A78A-B278F27F099B Q42949426-AB0CCF5B-6844-4EBB-9E9E-458CC06B426B Q43110200-E25F3749-7223-45D0-9C9E-81F61A28F526 Q44446648-E7AA3D97-CCC8-4A65-99AB-498BE8B46765 Q47308359-92FB531B-5C4B-42BD-AAF7-11EED44D3BF8 Q47721296-7B65B521-0F50-4C06-A44B-E7A89F0BB025 Q49120070-4FCC4B29-A8C1-43B0-918C-C3F2A49E2E74 Q55354364-732767E7-D289-41A0-84C6-D33D1E9D02EB Q57990336-C4235E2C-1533-4679-926D-C86EF6982040 Q59310906-040787E5-C8B8-4EAD-9B56-44256805A4F7

P2860

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

http://www.wikidata.org/entity/Q36807446

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@ast

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@en

type

label

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@ast

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@en

prefLabel

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@ast

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@en

P1433

Q36807446-8586313E-6E6F-434D-A2F2-FF0C3A239493

P1476

Q36807446-B475C355-BC05-4574-9090-5368F8246D2B

P2093

Q36807446-55022EDE-185A-4485-B5E0-5913B08E117C

Q36807446-68C75516-66A5-49D7-988C-3982D41C641C

Q36807446-6E38D4A9-5753-4B0B-9076-D30EE54943D4

Q36807446-A93772E9-6F9C-4D69-9A25-53D17783B481

Q36807446-B7FC3D55-0370-41E3-B611-0E627F63C80E

Q36807446-C32C9E57-E939-42CA-AC05-607A635CE9BD

P2860

Q36807446-0242596A-AA2A-4F54-A558-5F1F76315A97

Q36807446-0EFBA3FB-2C83-4E87-92F0-60A93A0D2F96

Q36807446-11BE76C4-B419-4B40-8378-9E7C4C487AFC

Q36807446-14AF5AA2-B12F-4AF4-ADA0-05F7C5B0E345

Q36807446-24AE0D33-B644-4E4C-B296-D11F0FFFECB6

Q36807446-35D8BA16-13B6-4FC0-92BA-452F93EAD03C

Q36807446-49B0D349-6015-4547-B3AA-F3707D8C637E

Q36807446-50D5CD0F-F49E-41C6-B3F5-F5F335CFFAE0

Q36807446-53E4038B-4FCE-40B9-A960-AB599739CF1C

Q36807446-61AA2168-3CEF-48D0-9091-894112FA8105

P304

Q36807446-BB6A684D-A9AB-440A-90B0-D7C983729842

P31

Q36807446-447AD47E-AF1F-4144-9A52-663F296A0967

P356

Q36807446-B75CDF5E-C069-4B6F-91A5-84C87CF80006

P407

Q36807446-83014F4C-7ED2-4387-84EF-91BD9E83F33C

P433

Q36807446-47BF3A77-7DF0-4C9D-9DA5-BA125A44B35F

P478

Q36807446-A5B362D6-A5DE-4391-9E34-CDA81A9EBC9D

P50

Q36807446-74A4F114-AD95-49E9-B92F-1DE5AE57DF8B

P577

Q36807446-821F946B-81CB-4A8A-9E7F-48C8C3297BBA

P5875

Q36807446-CC6067AE-AE3C-4307-A271-5B0AC15F9F9A

P698

Q36807446-127C6A9E-917F-4C8A-B793-33A279FD4035

P921

Q36807446-2A53FA0E-0195-4D5E-B9B9-8AC3BCC0B2B4

P932

Q36807446-79119727-2531-4E84-AD88-DBDC1AB464CC

P356

P1433

P1476

Cost-effectiveness of intensif ...... ctions from the Steno-2 study.

@en

P2093

Andrew J Palmer

http://www.w3.org/2001/XMLSchema#string

Daniel M D Tucker

http://www.w3.org/2001/XMLSchema#string

Hans-Henrik Parving

http://www.w3.org/2001/XMLSchema#string

Morten Lammert

http://www.w3.org/2001/XMLSchema#string

Peter Gaede

http://www.w3.org/2001/XMLSchema#string

William J Valentine

http://www.w3.org/2001/XMLSchema#string

P2860

Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.

One thousand health-related quality-of-life estimates.

Handling uncertainty in cost-effectiveness models.

Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.

Standards of medical care for patients with diabetes mellitus.

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

P304

1510-1515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC07-2452

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Oluf Borbye Pedersen

P577

2008-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5409571

http://www.w3.org/2001/XMLSchema#string

P698

18443195

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2494636

http://www.w3.org/2001/XMLSchema#string